Michael Wurl
Solvay
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Michael Wurl.
Bioorganic & Medicinal Chemistry Letters | 2003
Marco Franchi; Daniela Vullo; Enzo Gallori; Jochen Antel; Michael Wurl; Andrea Scozzafava; Claudiu T. Supuran
In addition to sulfonamides, metal complexing anions represent the second class of inhibitors of the zinc enzyme carbonic anhydrase (CA, EC 4.2.1.1). The first inhibition study of the mitochondrial isozyme CA V (of murine and human origin) with anions is reported here. Inhibition data of the cytosolic isozymes CA I and CA II as well as the membrane-bound isozyme CA IV with a large number of anionic species such as halides, pseudohalides, bicarbonate, nitrate, hydrosulfide, arsenate, sulfamate, and sulfamidate and so on, are also provided for comparison. Isozyme V has an inhibition profile by anions completely different to those of CA I and IV, but similar to that of hCA II, which may have interesting physiological consequences. Similarly to hCA II, the mitochondrial isozymes show micro-nanomolar affinity for sulfonamides such as sulfanilamide and acetazolamide.
Bioorganic & Medicinal Chemistry Letters | 2008
Anna Di Fiore; Carlo Pedone; Jochen Antel; Harald Waldeck; Andreas Witte; Michael Wurl; Andrea Scozzafava; Claudiu T. Supuran; Giuseppina De Simone
Ethoxzolamide, an almost forgotten inhibitor of the metalloenzyme carbonic anhydrase (CA, EC 4.2.1.1), is the only classical inhibitor whose structure in adduct with any isoform was not reported yet. We report here the inhibition data of this molecule with the 12 catalytically active mammalian isozymes (CA I-CA XIV) and the X-ray crystal structure with the cytosolic, ubiquitous isoform CA II. These data are presumably useful for the design of novel CA inhibitors, targeting various CA isozymes, considering that ethoxzolamide was already the lead molecule to obtain the second generation inhibitors, dorzolamide and brinzolamide, clinically used antiglaucoma agents with topical action, as well as various other investigational agents.
Bioorganic & Medicinal Chemistry Letters | 2005
Giuseppina De Simone; Anna Di Fiore; Valeria Menchise; Carlo Pedone; Jochen Antel; Angela Casini; Andrea Scozzafava; Michael Wurl; Claudiu T. Supuran
Archive | 1996
Harald Waldeck; Dagmar Hoeltje; Josef Messinger; Jochen Antel; Michael Wurl; Dirk Thormaehlen
Bioorganic & Medicinal Chemistry | 2007
Rosa Maria Vitale; Carlo Pedone; Pietro Amodeo; Jochen Antel; Michael Wurl; Andrea Scozzafava; Claudiu T. Supuran; Giuseppina De Simone
Bioorganic & Medicinal Chemistry Letters | 2004
Alessio Innocenti; Michael Firnges; Jochen Antel; Michael Wurl; Andrea Scozzafava; Claudiu T. Supuran
Bioorganic & Medicinal Chemistry Letters | 2005
Alessio Innocenti; Michael Firnges; Jochen Antel; Michael Wurl; Andrea Scozzafava; Claudiu T. Supuran
Archive | 1996
Harald Waldeck; Dagmar Höltje; Josef Messinger; Jochen Antel; Michael Wurl; Dirk Thormählen
Bioorganic & Medicinal Chemistry Letters | 2005
Alessio Innocenti; Jochen Antel; Michael Wurl; Daniela Vullo; Michael Firnges; Andrea Scozzafava; Claudiu T. Supuran
Archive | 1998
Harald Waldeck; Joerg Meil; Dirk Thormaehlen; Michael Wurl